目的 探讨龙生蛭胶囊联合尼莫地平片治疗急性脑梗死的临床疗效。方法 选取2016年4月-2017年4月于丹凤县医院就诊的192例急性脑梗死患者作为研究对象，将所有患者随机、双盲分为对照组和治疗组，每组各96例。对照组患者口服尼莫地平片，2片/次，3次/d；治疗组在对照组治疗的基础上口服龙生蛭胶囊，5粒/次，3次/d。两组患者均连续治疗2周。观察两组患者的临床疗效，同时比较两组治疗前后的神经功能评分、血清学指标和不良反应发生情况。结果 治疗后，对照组和治疗组的临床有效率分别为84.38%、94.79%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者中国脑卒中临床神经功能缺损程度评分量表（CSS）评分和美国国立卫生研究院卒中量表（NIHSS）评分均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组CSS评分和NIHSS评分显著低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者血清超敏C反应蛋白（hs-CRP）、神经元特异性烯醇化酶（NSE）、人内皮素1（ET-1）水平均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组血清学指标水平显著低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗期间，对照组不良反应发生率为11.46%，显著高于治疗组的3.13%，两组比较差异具有统计学意义（P<0.05）。结论 龙生蛭胶囊联合尼莫地平片治疗急性脑梗死疗效显著，可显著改善患者的神经功能评分，降低炎性指标，安全性高，具有一定的临床推广价值。

Objective To explore the clinical effect of Longshengzhi Capsules combined with Nimodipine Tablets in treatment of acute cerebral infarction. Methods Patients (192 cases) with acute cerebral infarction in Danfeng County Hospital from April 2016 to April 2017 were randomly divided into control and treatment groups, and each group had 96 cases. Patients in the control group were po administered with Nimodipine Tablets, 2 tablets/time, three times daily. Patients in the treatment group were po administered with Longshengzhi Capsules on the basis of the control group, 5 grains/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the neurological function scores, serological indicators, and the incidence of adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 84.38% and 94.79%, respectively, and there were differences between two groups (P<0.05). After treatment, the CSS and NIHSS scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the CSS and NIHSS scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the serum levels of hs-CRP, NSE, and ET-1 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the serological indicators levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). During the treatment, the adverse reactions rate in the control group was 11.46%, which was significantly higher than 3.13% in the treatment group, with significant difference between two groups (P<0.05). Conclusion Longshengzhi Capsules combined with Nimodipine Tablets has clinical curative effect in treatment of acute cerebral infarction, can significantly improve patients' neurological function score, reduce inflammatory indexes, with good safety which has a certain clinical application value.